News

The ingredients by SourceOne comprise specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, TocoSource Palm Tocotrienols, and VESIsorb (which is designed to enhance bioavailability of a variety

The randomized trial, called BATON-CRC, will enroll approximately 252 patients with no prior VEGF-targeted therapy at approximately 80 centers in the US, Canada, Australia and Europe, the company

GlaxoSmithKline will retain the existing rights for these products in countries outside the US. Terms of the agreement have not been disclosed. GSK will manufacture and supply Fortaz

Initiation of the trial entitles Dynavax to receive a $6m milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance. GSK has an exclusive option to obtain a

GSK’s portfolio of 17 OTC brands comprises pain relievers BC, Goody’s and Ecotrin; gastrointestinal brands Beano, Gaviscon, Phazyme, Tagamet, and Fiber Choice; and Sominex sleep aids. According to

The collaboration is focused on developing potential drug candidates to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis. In March 2011,

Ventrus Biosciences has licensed the North American rights to diltiazem hydrochloride cream from SLA Pharma. Initial top-line data from the randomized, double-blind study is expected to be available

As per the previous agreement, UniPharma had the exclusive right to distribute Radient’s cancer test in Taiwan. The expanded distribution agreement includes Singapore, Hong Kong and Macau. As

Under the terms of the collaboration, Anika will receive an initial payment of $2.5m besides being entitled to receive additional payments from after the launch of the product